Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries

Table 3

Hospitalized versus nonhospitalized patients for respiratory-related illness based on indication.

Indication	Hospitalized (%); 𝑁=875	Not hospitalized (%); 𝑁=12435	𝑃 value (𝜒^2)
Premature	384 (43.9)	8367 (67.3)	<0.0005
≤28 weeks GA	145 (16.6)	1805 (14.5)	0.101
29–32 weeks GA	175 (20.0)	4645 (37.4)	<0.0005
33–35 weeks GA	64 (7.3)	1902 (15.3)	<0.0005
CLD	128 (14.6)	920 (7.4)	<0.0005
HSCHD	146 (16.7)	1268 (10.2)	<0.0005
Other	217 (24.8)	1880 (15.1)	<0.0005
Neuromuscular disorders	28 (3.2)	125 (1.0)	<0.0005
Airway anomaly	45 (5.1)	299 (2.4)	<0.0005
Cystic fibrosis	9 (1.0)	222 (1.8)	0.115
Down syndrome	38 (4.3)	411 (3.3)	0.096
Pulmonary	37 (4.2)	309 (2.5)	0.003
Cardiac ≥ 2 years	4 (0.5)	38 (0.3)	0.355
Immunocompromised	9 (1.0)	41 (0.3)	0.005
Multisystem anomalies	18 (2.1)	113 (0.9)	0.004
Various medical disorders	29 (3.3)	322 (2.6)	0.188

HSCHD: hemodynamically significant congenital heart disease; CLD: chronic lung disease.